p21-Activated kinase inhibitors: a patent review

Bibliography

• Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006;6:459-71
   PubMed Web of Science ®Google Scholar
• Arias-Romero LE, Chernoff J. A tale of two Paks. Biol Cell 2008;100:97
   PubMed Web of Science ®Google Scholar
• Wells CM, Jones GE. The emerging importance of group II PAKs. Biochem J 2010;425:465-73
   PubMed Web of Science ®Google Scholar
• Sells MA, Knaus UG, Bagrodia S, Human p21-activated kinase (Pak1) regulates actin organisation in mammalian cells. Curr Biol 1997;7:202-10
   PubMed Web of Science ®Google Scholar
• Delorme V, Machacek M, DerMardirossian C, Cofilin activity downstream of Pak1 regulates cell protrusion efficiency by organising lamellipodium and lamella actin networks. Dev Cell 2007;13:646-62
   PubMed Web of Science ®Google Scholar
• Lei M, Lu W, Meng W, Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 2000;102:387-97
   PubMed Web of Science ®Google Scholar
• Eswaran J, Lee WH, Debreczeni JE, Crystal structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 2007;15:201-13
   PubMed Web of Science ®Google Scholar
• Zenke FT, King CC, Bohl BP, Identification of a central phosphorylation Site in p21-activated kinase regulating autoinhibition and kinase activity. J Biol Chem 1999;274:32565-73
   PubMedGoogle Scholar
• Ng Y-W, Raghunathan D, Chan PM, Why an a-loop phospho-mimetic fails to activate PAK1: understanding an inaccessible kinase state by molecular dynamics simulations. Struct Folding Des 2010;18:879-90
   Google Scholar
• Asrar S, Meng Y, Zhou Z, Regulation of hippocampal long-term potentiation by p21-activated protein kinase 1 (PAK1). Neuropharmacology 2009;56:73-80
   PubMedGoogle Scholar
• Allen JD, Jaffer ZM, Park S-J, p21-activated kinase regulates mast cell degranulation via effects on calcium mobilisation and cytoskeletal dynamics. Blood 2009;113:2695-705
   PubMed Web of Science ®Google Scholar
• Wang Z, Oh E, Clapp DW, Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo. J Biol Chem 2011;286:41359-67
   PubMed Web of Science ®Google Scholar
• Tian Y, Lei L, Cammarano M, Essential role for the Pak4 protein kinase in extraembryonic tissue development and vessel formation. Mech Dev 2009;126:710-20
   PubMed Web of Science ®Google Scholar
• Tian Y, Lei L, Minden A. A key role for Pak4 in proliferation and differentiation of neural progenitor cells. Dev Biol 2011;353:206-16
   PubMed Web of Science ®Google Scholar
• Dummler B, Ohshiro K, Kumar R, Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009;28:51-63
   PubMed Web of Science ®Google Scholar
• Qu J, Cammarano MS, Shi Q, Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol 2001;21:3523-33
   PubMedGoogle Scholar
• Callow MG, Clairvoyant F, Zhu S, Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 2002;277:550-8
   PubMed Web of Science ®Google Scholar
• Arias-Romero LE, Villamar-Cruz O, Pacheco A, A Rac-Pak signalling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 2010;29:5839-49
   PubMed Web of Science ®Google Scholar
• Ong CC, Jubb AM, Zhou W, p21-activated kinase 1: PAK'ed with potential. Oncotarget 2011;2:491-6
   Google Scholar
• Ong CC, Jubb AM, Haverty PM, Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci USA 2011;108(17):7177-82
   PubMed Web of Science ®Google Scholar
• Kimmelman AC, Hezel AF, Aguirre AJ, Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA 2008;105:19372-7
   PubMed Web of Science ®Google Scholar
• Parsons DW, Wang T-L, Samuels Y, Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792-2
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Adam L, Wang R-A, Regulatable expression of p21-activated Kinase-1 promotes anchorage-independent growth and abnormal organisation of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 2000;275:36238-44
   PubMed Web of Science ®Google Scholar
• Liu Y, Xiao H, Tian Y, The Pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res 2008;6:1215-24
   PubMed Web of Science ®Google Scholar
• Wang R-A, Zhang H, Balasenthil S, PAK1 hyperactivation is sufficient for mammary gland tumour formation. Oncogene 2006;25:2931-6
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen N, Cui X, The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumourigenesis. Oncogene 2010;29:5883-94
   PubMedGoogle Scholar
• Holm C, Rayala S, Jirstrom K, Association between Pak1 expression and subcellular localisation and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006;98:671-80
   PubMedGoogle Scholar
• Van den Broeke C, Radu M, Chernoff J, An emerging role for p21-activated kinases (Paks) in viral infectiontas. Trends Cell Biol 2010;20:160-9
   PubMedGoogle Scholar
• Van den Broeke C, Radu M, Deruelle M, Alphaherpesvirus US3-mediated reorganisation of the actin cytoskeleton is mediated by group A p21-activated kinases. Proc Natl Acad Sci USA 2009;106:8707-12
   PubMed Web of Science ®Google Scholar
• Pascua PNQ, Lee J-H, Song M-S, Role of the p21-activated kinases (PAKs) in influenza A virus replication. Biochem Biophys Res Commun 2011;414:569-74
   Google Scholar
• Konig R, Stertz S, Zhou Y, Human host factors required for influenza virus replication. Nature 2010;463:813-17
   PubMed Web of Science ®Google Scholar
• Nguyen D, Wolff K, Yin H, “UnPAKing” human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J Virol 2006;80:130-7
   PubMed Web of Science ®Google Scholar
• The Genomics Institute of the Novartis Research Foundation: Methods For Identifying Compounds That Inhibit HIV Infection. WO2006132681; 2006
   Google Scholar
• Liberali P, Kakkonen E, Turacchio G, The closure of Pak1-dependent macropinosomes requires the phosphorylation of CtBP1/BARS. EMBO J 2008;27:970-81
   Google Scholar
• Amstutz B, Gastaldelli M, Kalin S, Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3. EMBO J 2008;27:956-69
   PubMed Web of Science ®Google Scholar
• Meng J, Meng Y, Hanna A, Abnormal long-lasting synaptic plasticity and cognition in mice lacking the mental retardation gene Pak3. J Neurosci 2005;25:6641-50
   PubMed Web of Science ®Google Scholar
• Huang W, Zhou Z, Asrar S, p21-Activated Kinases 1 and 3 control brain size through coordinating neuronal complexity and synaptic properties. Mol Cell Biol 2011;31:388
   PubMed Web of Science ®Google Scholar
• Tian Y, Lei L, Minden A. A key role for Pak4 in proliferation and differentiation of neural progenitor cells. Dev Biol 2011;353:206-16
   PubMed Web of Science ®Google Scholar
• Nekrasova T, Jobes ML, Tingh JH, Targeted disruption of the Pak5 and Pak6 genes in mice leads to deficits in learning and locomotion. Dev Biol 2008;322:95-108
   PubMed Web of Science ®Google Scholar
• Kreis P, Barnier J-V. PAK signalling in neuronal physiology. Cell Signal 2009;21:384-93
   PubMed Web of Science ®Google Scholar
• Ma Q-L, Yang F, Calon F, p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem 2008;283:14132-43
   Web of Science ®Google Scholar
• Zhao L, Ma Q-L, Calon F, Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 2006;9:234-42
   PubMed Web of Science ®Google Scholar
• Allen KM, Gleeson JG, Bagrodia S, PAK3 mutation in nonsyndromic X-linked mental retardation. Nat Genet 1998;20:25-30
   PubMed Web of Science ®Google Scholar
• Peippo M, Koivisto AM, Sarkamo T, PAK3 related mental disability: further characterisation of the phenotype. Am J Med Genet A 2007;143:2406-16
   Google Scholar
• Say E, Tay H-G, Zhao Z-S, A functional requirement for PAK1 binding to the KH(2) domain of the fragile X protein-related FXR1. Mol Cell 2010;38:236-49
   PubMed Web of Science ®Google Scholar
• Afraxis, Inc. Compounds for treating neuropsychiatric conditions. WO2010071846; 2010
   Google Scholar
• Afraxis, Inc. 8-Ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders. WO2011044535; 2011
   Google Scholar
• Afraxis, Inc. 6-(Sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders. WO2011156646; 2011
   Google Scholar
• Afraxis, Inc. 6-(Ethynyl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders. WO2011156786; 2011
   Google Scholar
• Afraxis, Inc. 8-(Heteroarylmethyl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders. WO2011156640; 2011
   Google Scholar
• Afraxis, Inc. 8-(Sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders. WO2011156780; 2011
   Google Scholar
• Afraxis, Inc. 8-(2'-Heterocyclyl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders. WO2011156775; 2011
   Google Scholar
• Afraxis, Inc. Pyrrolopyrazoles for treating CNS disorders. WO2011044264; 2010
   Google Scholar
• Afraxis, Inc. Methods for treating neuropsychiatric conditions. WO2009086204; 2009
   Google Scholar
• Massachusetts Institute of Technology and Ambit Biosciences Corp. Small Molecule PAK Inhibitors. WO2008060448; 2008.
   Google Scholar
• Massachusetts Institute of Technology: PAK Modulators. WO2008063933; 2008
   Google Scholar
• Patyna S, Laird AD, Mendel DB, SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumour activity. Mol Cancer Ther 2006;5:1774-82
   PubMed Web of Science ®Google Scholar
• Erlichman C, Hidalgo M, Boni JP, Phase I Study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumours. J Clin Oncol 2006;24:2252-60
   PubMed Web of Science ®Google Scholar
• Zhang S, Suvannasankha A, Crean CD, OSU-03012, a Novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007;13:4750-8
   PubMed Web of Science ®Google Scholar
• Porchia LM, Guerra M, Wang Y-C, 2-Amino-N-Acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 2007;72:1124-31
   PubMed Web of Science ®Google Scholar
• Huang Q, Shen H-M, Ong C-N. Emodin inhibits tumour cell migration through suppression of the phosphatidylinositol 3-kinase-Cdc42/Rac1 pathway. Cell Mol Life Sci 2005;62:1167-75
   PubMedGoogle Scholar
• AstraZeneca UK Ltd. Substituted Heterocycles And Their Use As CHK1, PDK1 AND PAK Inhibitors. WO2006106326; 2006
   Google Scholar
• Baska F, Szantai-Kis C, Greff Z, Development of PAK1 kinase inhibitors with “in silico” modeling methods. Acta Pharm Hung 2010;80:155-61
   PubMedGoogle Scholar
• Astex Therapeutics Ltd. Therapeutic Uses Of 1-Cyclopropyl-3-[3-(5-Morpholin-4-ylmethyl-1H-Benzoimidazol-2-yl)-1H-Pyrazol-4-yl]-Urea. WO2009138799; 2009
   Google Scholar
• Astex Therapeutics Ltd. Pyrazole Compounds That Modulate The Activity Of Cdk, Gsk And Aurora Kinases. WO2006070195; 2006
   Google Scholar
• Astex Therapeutics Ltd. Pharmaceutical Compounds. WO2007077435; 2007
   Google Scholar
• Fox Chase Cancer Center. Methods of screening for inhibitors of autoinhibited proteins. WO2006029337; 2006
   Google Scholar
• Deacon SW, Beeser A, Fukui JA, An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008;15:322-31
   PubMedGoogle Scholar
• Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009;8:2559-65
   PubMed Web of Science ®Google Scholar
• President and Fellows of Harvard College and The Brigham and Women's Hospital, Inc. Compositions And Method For Inhibiting Tumour Growth. WO2010141738; 2010
   Google Scholar
• Pfizer: This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumours - ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00932126 [Last accessed 25 December 2011]
   Google Scholar
• Pharmacia Italia S.P.A. Heterobicyclic Pyrazole Derivatives As Kinase Inhibitors. WO2004007504; 2004
   Google Scholar
• Bindi S, Fancelli D, Alli C, Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumour activity. Bioorg Med Chem 2010;18:7113-20
   PubMedGoogle Scholar
• Carpinelli P, Ceruti R, Giorgini ML, PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68
   PubMed Web of Science ®Google Scholar
• Fancelli D, Moll J, Varasi M, 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favourable antitumour kinase inhibition profile. J Med Chem 2006;49:7247-51
   PubMed Web of Science ®Google Scholar
• Fancelli D, Berta D, Bindi S, Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem 2005;48:3080-4
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors. WO2007023382; 2007
   Google Scholar
• Bebbington D, Binch H, Charrier J-D, The discovery of the potent Aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 2009;19:3586-92
   PubMed Web of Science ®Google Scholar
• Ioannidis S, Lamb ML, Wang T, Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway. J Med Chem 2011;54:262-76
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Advanced drug delivery reviews : experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Leeson PD, St-Gallay SA. The influence of the “organisational factor” on compound quality in drug discovery. Nat Rev Drug Discov 2011;10:749-65
   PubMed Web of Science ®Google Scholar
• Pfizer Products Inc. Carbonylaminopyrrolopyrazoles, Potent Kinase Inhibitors. WO2007/072153; 2007
   Google Scholar
• Pfizer, Inc. Pyrrolopyrazoles, Potent Kinase Inhibitors. WO2006072831; 2006
   Google Scholar
• Murray BW, Guo C, Piraino J, Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signalling and tumour growth. Proc Natl Acad Sci USA 2010;107:9446-51
   PubMed Web of Science ®Google Scholar
• Guo C. Discovery of p21-Activated Kinase Inhibitor PF-3758309. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 16 November 2009; Boston, Massachusetts
   Google Scholar
• Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430-1
   PubMed Web of Science ®Google Scholar
• Barreiro EJ, Kummerle AE, Fraga CAM. The methylation effect in medicinal chemistry. Chem Rev 2011;111:5215-46
   PubMed Web of Science ®Google Scholar
• Mileshkin LR, Rosen LS, Blumenkopf T, Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumours. J Clin Oncol 2011;29(Suppl):abstract e13607^
   Google Scholar
• Rosen L, Blumenkopf T, Breazna A, Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumours [Poster A177]. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 12 – 16 November 2011; San Francisco, California
   Google Scholar
• Zhang J, Wang J, Guo Q, LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett 2011;317:24-32
   PubMedGoogle Scholar
• Maksimoska J, Feng L, Harms K, Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 2008;130:15764-5
   Web of Science ®Google Scholar
• Meggers E. From conventional to unusual enzyme inhibitor scaffolds: the quest for target specificity. Angew Chem Int Ed 2011;50:2442-8
   PubMed Web of Science ®Google Scholar
• Lin H, Yamashita DS, Zeng J, 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett 2010;20:679-83
   PubMed Web of Science ®Google Scholar
• Li R, Stafford JA. Kinase inhibitor drugs. John Wiley & Sons; New Jersey: 2009. ISBN: 978-0-470-27829-1
   Google Scholar
• Klebl B, ller GM, Hamacher M, Protein kinases as drug targets. John Wiley & Sons; New Jersey: 2011. ISBN: 978-3-527-63349-4
   Google Scholar
• Sanofi-Aventis Deutschland GmbH: Use of PAK inhibitor for the treatment of a joint disease. WO2005011721; 2005
   Google Scholar
• Bamborough P, Brown MJ, Christopher JA, J Med Chem 2011;54:5131-43
   PubMed Web of Science ®Google Scholar
• Wang J, Yan M, Zhao D, Pharmacophore identification of PAK4 inhibitors. Mol Simul 2010;36:53-7
   Web of Science ®Google Scholar
• Wager TT, Hou X, Verhoest PR, Moving beyond rules: the development of a Central Nervous System Multiparameter Optimisation (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010;1:435-49
   PubMed Web of Science ®Google Scholar